Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Expedited Ind Pilot topic
No spam. Unsubscribe anytime.
FDA outlines expedited IND pilot to speed first‑in‑human trials
Summary
FDA officials described 'Operation Trialblazer' and an expedited IND pilot that pairs sponsors with qualified research institutions for rolling pre‑IND submissions, saying the agency will keep full review authority while testing whether earlier review and IRB coordination can shorten time to first patient.
Grace Graham, a deputy commissioner at HHS who opened the webinar, and senior FDA officials detailed a pilot program under Operation Trialblazer intended to shorten the time from early development to first‑in‑human clinical trials. The agency said the effort will use sponsor–qualified research institution (QRI) partnerships and a rolling submission process to resolve issues earlier and reduce delays after a formal IND filing.
Ben Cook, senior adviser in the Office of the Commissioner, framed the effort as a response to changing global competition for early‑stage trials and cited a study warning of tangible risks if the U.S. does not act: "as of 2025, The United States has 3 years to reverse this trend or the offshoring of trials will be irreversible," he said. FDA officials emphasized the pilot is proposed and that the agency is soliciting public comment on the RFI (published June 24 and whose comment period was extended to August 24).
The pilot will invite sponsor–QRI pairs to apply; FDA said it anticipates opening applications in September and selecting participants in calendar Q4. Agency staff stressed FDA will retain full regulatory authority during the pilot and that selection will aim for diversity across therapeutic areas, sponsor sizes and QRI types. Officials also said the pilot is limited to commercial INDs.
